Acute pain associated with oxaliplatin infusion: Case report and literature review

Journal of Oncology Pharmacy Practice

Volumn 18, Issue 4, 2012, Pages 421-424

  Clay, Timothy D ^a   Ashley, David A ^a,b  

^a GEELONG HOSPITAL   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

Author keywords

neurotoxicity; Oxaliplatin; pain

Indexed keywords

DIAZEPAM; FLUOROURACIL; FOLINIC ACID; GRANISETRON; HYDROCORTISONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXALIPLATIN; PROMETHAZINE; SCOPOLAMINE; TRAMADOL;

ACUTE ABDOMEN; ADULT; ALCOHOL CONSUMPTION; ANALGESIA; APPENDECTOMY; CANCER PATIENT; CANCER STAGING; CASE REPORT; COLON ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DISTANT METASTASIS; DISTRESS SYNDROME; DRUG WITHDRAWAL; HEADACHE; HIP PAIN; HUMAN; INJECTION PAIN; KNEE PAIN; LAPAROTOMY; LEG PAIN; LOW BACK PAIN; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PAIN ASSESSMENT; PELVIS PAIN SYNDROME; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SHOULDER PAIN; SIGMOID; SMOKING; THIGH PAIN; TREATMENT WITHDRAWAL; VOMITING;

ACUTE PAIN; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS;

EID: 84869069414     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155211428999     Document Type: Review

References (25)

1. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000 ; 18 (16). 2938-2947
2. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic CRC. J Clin Oncol. 2004 ; 22 (1). 23-30
3. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005 ; 23 (22). 4866-4875
4. Goldberg RM, Sargent DJ, Morton RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American intergroup trial. J Clin Oncol. 2006 ; 24 (21). 3347-3353
5. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004 ; 350 (23). 2343-2351
6. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 ; 358 (1). 36-46
7. Conroy T, Desseigne F, Ychou M, et al. Randomized Phase III trial comparing FOLFIRINOX versus gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma: preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial [abstract]. J Clin Oncol. 2010 ; 28 (suppl 7s). Abstract 4010 - Abstract 4010
8. Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol. 2002 ; 29 (suppl 15). 11-20
9. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventative measures. Semin Oncol. 2002 ; 29 (suppl 15). 21-33
10. Lehky T, Leonard G, Wilson R, et al. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve. 2004 ; 29: 387-392
11. Grolleau F, Gamelin L, Boisdron-Celle M, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol. 2001 ; 85: 2293-2297
12. Webster R, Brain K, Wilson R, et al. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol. 2005 ; 146: 1027-1039
13. Adelsberger H, Quasthoff S, Grosskreutz J, et al. The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons. Euro J Pharmacol. 2000 ; 406: 25-32
14. Wilson R, Lehky T, Thomas R, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002 ; 20: 1767-1774
15. Park S, Goldstein D, Lin C, et al. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol. 2009 ; 27: 1243-1249
16. Saadati H, Saif M. Oxaliplatin-induced hyperexcitability syndrome in a patient with pancreatic cancer. J Pancreas. 2009 ; 10 (4). 459-461
17. Saif M, Hashmi S. Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer. Cancer Chemother Pharmacol. 2008 ; 61: 349-354
18. Una E. Atypical presentation of acute neurotoxicity secondary to oxaliplatin. J Oncol Pharm Practice. 2010 ; 16: 280-282
19. Winquist E, Vincent M, Stadler W. Acute bilateral abducens paralysis due to oxaliplatin. J Natl Cancer I. 2003 ; 95: 488-489
20. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 ; 30 (2). 239-245
21. Petrioli R, Pascussi A, Francini E, et al. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol. 2008 ; 61: 105-111
22. Hochster H, Grothey A, Childs B. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Onc. 2007 ; 25: 4028-4029
23. Hochster H, Grothey A, Shpilsky A and Childs B. Effect of intravenous (IV) calcium and magnesium (Ca/Mg) versus placebo on reponse to FOLFOX+bevacizumab (BEV) in the CONcePT trial. Abstract 280, 2008. In: ASCO Gastrointestinal Cancers Symposium, Orlando, Florida, USA, 25-27 Jan 2008.
24. Kurniali P, Luo L, Weitberg A. Role of calcium/magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients. Oncology. 2010 ; 24 (3). 289-292
25. Pasetto L, D'Andrea M, Rossi E, Monfardini S. Oxaliplatin-related neurotoxicity: how and why?. Crit Rev Onc Hem. 2006 ; 59: 159-168